AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31283481 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Haptic Scenario (visual, auditory, and passive haptic) - N = 13
Number of subjects: 37
Study 31283481 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory Scenario (visual, auditory, wind, passive haptic, vibration, and scent) - N = 12
Number of subjects: 37
Study 31283481 — intervention group
Group type: COMPARATOR
Intervention: Control Scenario (visual and auditory) - N = 12
Number of subjects: 37
Study 29882727 — intervention group
Group type: EXPERIMENTAL
Intervention: e-prescription
Number of subjects: 95
Study 27684037 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief written materials (intervention group)
Number of subjects: 135
Study 27684037 — intervention group
Group type: COMPARATOR
Intervention: Genetic counseling session at a familial cancer clinic (usual-care group)
Number of subjects: 135
Study 26044464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (150 kcal, 20 g whey protein, 800 IU vitamin D)
Number of subjects: 150
Study 26044464 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (30 kcal, non-nutritive)
Number of subjects: 150
Study 24776045 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stents
Number of subjects: 686
Study 24776045 — intervention group
Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting stents
Number of subjects: 686
Study 21670338 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital grading of diabetic retinopathy severity
Number of subjects: 310
Study 21670338 — intervention group
Group type: COMPARATOR
Intervention: Film grading of diabetic retinopathy severity
Number of subjects: 310
Study 19565475 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg CP-690,550 twice daily
Number of subjects: 264
Study 19565475 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg CP-690,550 twice daily
Number of subjects: 264
Study 19565475 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg CP-690,550 twice daily
Number of subjects: 264
Study 19565475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 19565475 — intervention group
Group type: EXPERIMENTAL
Intervention: All CP-690,550 treatment arms
Number of subjects: 264
Study 19565475 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg and 30 mg CP-690,550
Number of subjects: 264
Study 17001661 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin alone or combined with paclitaxel and/or cisplatin
Number of subjects: 1151
Study 15302243 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation using an exercise regime
Number of subjects: 108
Study 15302243 — intervention group
Group type: COMPARATOR
Intervention: Soft collar treatment for 3 weeks followed by the same exercise regime
Number of subjects: 108
Study 11404114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held dynamometry for measuring maximum isometric muscle force in boys and girls.
Number of subjects: 270
Study 9436283 — intervention group
Group type: EXPERIMENTAL
Intervention: T1c tumors
Number of subjects: 51
Study 9436283 — intervention group
Group type: COMPARATOR
Intervention: Non-T1c tumors with PSA < 4 ng/ml
Number of subjects: 51
Study 8312586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 257
Study 8312586 — intervention group
Group type: COMPARATOR
Intervention: Not treated with tamoxifen
Number of subjects: 257
Study 30244209 — intervention group
Group type: EXPERIMENTAL
Intervention: 2011 Accreditation Council for Graduate Medical Education resident duty hour rules
Number of subjects: 63
Study 30244209 — intervention group
Group type: COMPARATOR
Intervention: More flexible intern shift length and number of hours off between shifts
Number of subjects: 63
Study 27501614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-Articular Infiltration (IA) with 15 mL of 0.25% bupivacaine into the knee joint and 5 mL infiltrated along the incision sites.
Number of subjects: 40
Study 27501614 — intervention group
Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB) with 20 mL of 0.25% bupivacaine under ultrasound guidance.
Number of subjects: 40
Study 24853809 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin only (32%)
Number of subjects: 100
Study 24853809 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and oral antidiabetics (OADs) (15%)
Number of subjects: 100
Study 24853809 — intervention group
Group type: EXPERIMENTAL
Intervention: OADs only (27%)
Number of subjects: 100
Study 24853809 — intervention group
Group type: EXPERIMENTAL
Intervention: No drugs (26%)
Number of subjects: 100
Study 23011325 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium‐containing preparation administrated orally for 1 to 3 months
Number of subjects: 78
Study 23011325 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 78
Study 20498618 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/hydrochlorothiazide (320/25 mg)
Number of subjects: 412
Study 20498618 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide plus amlodipine (25 mg and 10 mg)
Number of subjects: 412
Study 18677236 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16
Study 18677236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% polyethylene glycol/0.3% propylene glycol
Number of subjects: 16
Study 18677236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% carboxymethylcellulose
Number of subjects: 16
Study 18677236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil emulsion
Number of subjects: 16
Study 18677236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low viscosity carboxymethylcellulose
Number of subjects: 16
Study 18677236 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate viscosity hydroxypropylmethylcellulose-containing formulation
Number of subjects: 16
Study 15886236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg ACTH stimulation in group B (hospitalized medical patients)
Number of subjects: 74
Study 15886236 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg ACTH stimulation in group B (hospitalized medical patients)
Number of subjects: 74
Study 15886236 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg ACTH stimulation in group C (patients undergoing coronary artery bypass grafting)
Number of subjects: 74
Study 15886236 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH stimulation in group C (surgical patients)
Number of subjects: 74
Study 15886236 — intervention group
Group type: COMPARATOR
Intervention: 1 microg and 250 microg ACTH stimulation in groups A (ambulatory controls) and B (medical patients)
Number of subjects: 74
Study 15886236 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of relative adrenal insufficiency
Number of subjects: 74
Study 12598280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway Fastrach (ILM)
Number of subjects: 150
Study 12598280 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachlight lightwand (LW)
Number of subjects: 150
Study 12598280 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (LS)
Number of subjects: 150
Study 10100273 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome) - 60 mg/m2, intravenous infusion, once every 4 weeks, up to 600 mg/m2 cumulative dose
Number of subjects: 14
Study 10100273 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome)
Number of subjects: 14
Study 8775524 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty (PTCA)
Number of subjects: 100
Study 8775524 — intervention group
Group type: COMPARATOR
Intervention: Medical strategy
Number of subjects: 100
Study 1672392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular magnesium sulphate every week for 6 weeks
Number of subjects: 32
Study 1672392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6512802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Augmentin (amoxycillin and clavulanic acid)
Number of subjects: 0
Study 30475777 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal pressure titration PEEP (n = 12)
Number of subjects: 23
Study 30475777 — intervention group
Group type: COMPARATOR
Intervention: ARDSNet (PEEP-FiO2 table) titration PEEP (n = 11)
Number of subjects: 23
Study 29548270 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-Pattern Training (MPT)
Number of subjects: 28
Study 26973269 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation therapy
Number of subjects: 106
Study 26973269 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitation therapy after leaving ICU)
Number of subjects: 106
Study 24738933 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B1 100 mg daily for three months
Number of subjects: 110
Study 24738933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 22343669 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) during HSCT
Number of subjects: 26
Study 19188102 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived weight status
Number of subjects: 899
Study 17999764 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of vascular risk factors including blood pressure, waist circumference, body mass index (BMI), ankle brachial index (ABI), and total and HDL cholesterol.
Number of subjects: 402
Study 15257032 — intervention group
Group type: EXPERIMENTAL
Intervention: FK778 high-level group (2 x 600 mg/day FK778 followed by 150 mg/day)
Number of subjects: 149
Study 15257032 — intervention group
Group type: EXPERIMENTAL
Intervention: FK778 low-level group (1 x 600 mg/day FK778 followed by 75 mg/day)
Number of subjects: 149
Study 15257032 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 149
Study 15257032 — intervention group
Group type: EXPERIMENTAL
Intervention: FK778 high-level group
Number of subjects: 149
Study 15257032 — intervention group
Group type: EXPERIMENTAL
Intervention: FK778 low-level group
Number of subjects: 149
Study 15257032 — intervention group
Group type: EXPERIMENTAL
Intervention: FK778 treatment
Number of subjects: 149
Study 11668380 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (hemodilution with autologous blood predonations)
Number of subjects: 22
Study 11668380 — intervention group
Group type: COMPARATOR
Intervention: Group II (control with homologous blood transfusion)
Number of subjects: 22
Study 9851959 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg administered intravenously)
Number of subjects: 20
Study 9851959 — intervention group
Group type: COMPARATOR
Intervention: Tilt test
Number of subjects: 20
Study 7988129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-triggered synchronous intermittent mandatory ventilation at 60% of the assist-control rate
Number of subjects: 8
Study 7988129 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-triggered synchronous intermittent mandatory ventilation at 40% of the assist-control rate
Number of subjects: 8
Study 7988129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-triggered synchronous intermittent mandatory ventilation at 20% of the assist-control rate
Number of subjects: 8
Study 7988129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-triggered synchronous intermittent mandatory ventilation
Number of subjects: 8
Study 7988129 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-triggered synchronous intermittent mandatory ventilation
Number of subjects: 8
Study 7988129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-time product
Number of subjects: 8
Study 2692315 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ASS daily
Number of subjects: 20
Study 2692315 — intervention group
Group type: COMPARATOR
Intervention: 500 mg ASS daily
Number of subjects: 20
Study 4601523 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth (De-Nol)
Number of subjects: 20
Study 4601523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31722446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg twice daily
Number of subjects: 214
Study 31722446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 10 or 15 mg twice daily
Number of subjects: 214
Study 31004141 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC) plus 48-hour positive airway pressure (PAP) therapy
Number of subjects: 21
Study 31004141 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 21
Study 28581341 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention including education for prescribers, auditing on metabolic monitoring, and feedback to mental health center leaders.
Number of subjects: 0
Study 26727829 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal correction of anemia with Erythropoietin β (Recormon®)
Number of subjects: 50
Study 26727829 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal correction of anemia (not achieving target hemoglobin)
Number of subjects: 50
Study 26727829 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin β (Recormon®)
Number of subjects: 50
Study 23495916 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA) with iCa titrated to 0.8-1.0 mm
Number of subjects: 15
Study 23495916 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA) with iCa titrated to 1.1-1.4 mm
Number of subjects: 15
Study 23495916 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 15
Study 20920136 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray catheter instillation
Number of subjects: 40
Study 20920136 — intervention group
Group type: COMPARATOR
Intervention: Standard injection through the working channel
Number of subjects: 40
Study 19564665 — intervention group
Group type: EXPERIMENTAL
Intervention: Triaxial accelerometer (RT3) wear time defined as 8 or more hours
Number of subjects: 0
Study 19564665 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of data to a 12-hour day
Number of subjects: 0
Study 19564665 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricting MVPA to activities occurring in bouts of 10 minutes or longer
Number of subjects: 0
Study 17491172 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion plus counseling plus access to CHESS SCRP (12 weeks)
Number of subjects: 284
Study 17491172 — intervention group
Group type: COMPARATOR
Intervention: Bupropion plus counseling
Number of subjects: 284
Study 15636571 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-level cervical arthroplasty with Bryan cervical artificial disc
Number of subjects: 13
Study 15636571 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-level cervical arthroplasty with Bryan cervical artificial disc
Number of subjects: 13
Study 11543752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 281
Study 11543752 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen plus codeine
Number of subjects: 281
Study 11543752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 9605375 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 30 microg/kg
Number of subjects: 50
Study 9605375 — intervention group
Group type: COMPARATOR
Intervention: Morphine 45 microg/kg
Number of subjects: 50
Study 8091435 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL)
Number of subjects: 14916
Study 8091435 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL) in normotensive subjects
Number of subjects: 14916
Study 8091435 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL) in men 60 years or younger
Number of subjects: 14916
Study 8091435 — intervention group
Group type: COMPARATOR
Intervention: Control subjects with lower homocyst(e)ine levels (bottom 80%)
Number of subjects: 14916
Study 3053207 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin 100 mg/m2 with cyclophosphamide 600 mg/m2
Number of subjects: 60
Study 3053207 — intervention group
Group type: COMPARATOR
Intervention: carboplatin 300 mg/m2 with cyclophosphamide 600 mg/m2
Number of subjects: 60
Study 3053207 — intervention group
Group type: COMPARATOR
Intervention: iproplatin 240 mg/m2 with cyclophosphamide 600 mg/m2
Number of subjects: 60
Study 3053207 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide/CHIP combination
Number of subjects: 60
Study 3053207 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide/CBDCA combination
Number of subjects: 60
Study 240979 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug group
Number of subjects: 0
Study 240979 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 31741562 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with levobupivacaine
Number of subjects: 60
Study 29789607 — intervention group
Group type: EXPERIMENTAL
Intervention: Microspirometry (MI) using COPD-6® microspirometers
Number of subjects: 416
Study 29789607 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 416
Study 27112712 — intervention group
Group type: COMPARATOR
Intervention: Pedicled single internal thoracic artery
Number of subjects: 2056
Study 27112712 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled bilateral internal thoracic artery
Number of subjects: 2056
Study 27112712 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized bilateral internal thoracic artery
Number of subjects: 2056
Study 27112712 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized single internal thoracic artery
Number of subjects: 2056
Study 24737141 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro fissure sealant
Number of subjects: 80
Study 24737141 — intervention group
Group type: COMPARATOR
Intervention: Fuji VII fissure sealant
Number of subjects: 80
Study 24737141 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fissure sealant technique (CST)
Number of subjects: 80
Study 24737141 — intervention group
Group type: EXPERIMENTAL
Intervention: Enameloplasty sealant technique (EST)
Number of subjects: 80
Study 22739107 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) for 60 min
Number of subjects: 6
Study 22739107 — intervention group
Group type: COMPARATOR
Intervention: Control (nonstimulated leg)
Number of subjects: 6
Study 22739107 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 6
Study 20056926 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemicraniectomy for malignant middle cerebral artery infarction
Number of subjects: 27
Study 16874485 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous TIL plus IL-2
Number of subjects: 88
Study 16874485 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 88
Study 15762943 — intervention group
Group type: EXPERIMENTAL
Intervention: Number-word sequence skill
Number of subjects: 0
Study 15762943 — intervention group
Group type: EXPERIMENTAL
Intervention: Solving doubles problems (e.g., 2 + 2 = ?)
Number of subjects: 0
Study 12168783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (HA gel)
Number of subjects: 28
Study 12168783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10341825 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 93
Study 10341825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 8564096 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (0.6 mg/kg/d)
Number of subjects: 18
Study 2405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved disease‐free survival of poor‐prognosis subgroups
Number of subjects: 0
Study 2405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved sanctuary therapy
Number of subjects: 0
Study 2405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortening of therapy duration
Number of subjects: 0
Study 2405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage of relapsed patients with better chemotherapy regimens
Number of subjects: 0
Study 2405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Number of subjects: 0
Study 2405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardization of staging systems
Number of subjects: 0
Study 2405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable in vitro tests of chemosensitivity and chemoresistance
Number of subjects: 0
Study 2405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitation of residual leukemia after remission induction
Number of subjects: 0
Study 2405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of drug‐resistant clones of cells
Number of subjects: 0
Study 2405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery of optimum therapy and supportive care
Number of subjects: 0
Study 7238342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal administration of gentamicin (40 mg, undiluted, 6-hourly)
Number of subjects: 20
Study 7238342 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 20
Study 31234886 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy (SCRT, 5 × 5 Gy) plus FOLFOX4
Number of subjects: 0
Study 31234886 — intervention group
Group type: COMPARATOR
Intervention: Long-course oxaliplatin and bolus of fluorouracil based preoperative long-course chemoradiotherapy (LCCRT, 50.4 Gy in 28 fractions)
Number of subjects: 0
Study 28840379 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + CTM
Number of subjects: 40
Study 28840379 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 40
Study 26308176 — intervention group
Group type: EXPERIMENTAL
Intervention: favipiravir 1,200 mg
Number of subjects: 56
Study 26308176 — intervention group
Group type: EXPERIMENTAL
Intervention: favipiravir 2,400 mg
Number of subjects: 56
Study 26308176 — intervention group
Group type: COMPARATOR
Intervention: moxifloxacin 400 mg
Number of subjects: 56
Study 26308176 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study 23229165 — intervention group
Group type: EXPERIMENTAL
Intervention: No water removal (NWR)
Number of subjects: 56
Study 23229165 — intervention group
Group type: COMPARATOR
Intervention: Water removal (WR)
Number of subjects: 56